Stockreport

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta, Inc.  (NKTX) 
PDF First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated auto [Read more]